Provided by Tiger Fintech (Singapore) Pte. Ltd.

Janux Therapeutics, Inc.

23.25
-1.0500-4.32%
Volume:323.84K
Turnover:7.64M
Market Cap:1.40B
PE:-12.94
High:24.35
Open:24.30
Low:23.21
Close:24.30
52wk High:71.71
52wk Low:21.97
Shares:60.09M
Float Shares:44.97M
Volume Ratio:0.48
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7966
EPS(LYR):-1.2836
ROE:-12.82%
ROA:-10.51%
PB:1.41
PE(LYR):-18.11

Loading ...

Janux Therapeutics Inc (JANX) Receives a New Rating from Guggenheim

TIPRANKS
·
Aug 19

Janux Therapeutics initiated with an Overweight at Piper Sandler

TIPRANKS
·
Aug 19

Stock Track | Janux Therapeutics Soars 5.05% Following Bank of America's Buy Rating Reiteration

Stock Track
·
Aug 13

Stock Track | Janux Therapeutics Soars 5.05% Following Bank of America's Buy Rating Reiteration

Stock Track
·
Aug 13

Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials

TIPRANKS
·
Aug 13

Janux Therapeutics Inc : Leerink Partners Cuts Target Price to $87 From $89

THOMSON REUTERS
·
Aug 12

Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target

TIPRANKS
·
Aug 11

Did a $10 Million Milestone from Merck Just Shift Janux Therapeutics' (JANX) Investment Narrative?

Simply Wall St.
·
Aug 10

BTIG Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Aug 08

Janux Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Optimistic Outlook for Janux Therapeutics: Strong Cash Position and Promising ‘007 Program Drive Buy Rating

TIPRANKS
·
Aug 08

Promising Pipeline and Financial Stability Support Buy Rating for Janux Therapeutics Inc

TIPRANKS
·
Aug 08

Janux Therapeutics Q2 EPS $(0.55) Misses $(0.49) Estimate

Benzinga
·
Aug 08

Janux (JANX) R&D Soars Revenue Misses

Motley Fool
·
Aug 08

Janux Therapeutics reports Q2 EPS (55c), consensus (47c)

TIPRANKS
·
Aug 08

BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.55

Reuters
·
Aug 08

Janux Therapeutics Reports Q2 2025 Net Loss of $33.9M, Increased R&D Expenses to $34.7M

Reuters
·
Aug 08

UBS Cuts Janux Therapeutics' Price Target to $65 From $69, Buy Rating Kept

MT Newswires Live
·
Jul 29

Janux Therapeutics: Strategic Innovations and Robust Pipeline Drive Buy Rating

TIPRANKS
·
Jul 28

UBS Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Jul 28